SCHEMBL5227372

SCHEMBL5227372

CCCCC1(CCCC)CSc2cc(OC)ccc2NC1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.52
MAOA P21397 3/20 0.52
SNCA P37840 3/20 0.46
NOX1 Q9Y5S8 3/20 0.41
HTT P42858 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MMP2 P08253 2/20 0.38
MMP9 P14780 2/20 0.38
MMP8 P22894 2/20 0.38
MMP13 P45452 2/20 0.38
PDE3B Q13370 2/20 0.37
PDE3A Q14432 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8024372 0.95 MAOB (0.50) MAOBMAOASNCANOX1HTT
SCHEMBL21585948 0.87 MAOB (0.57) MAOBMAOASNCANOX1HTT
SCHEMBL21585923 0.78 KMT2A (0.32) KMT2A
SCHEMBL22286608 0.78 LMNA (0.35) LMNAGAAMAPTKMT2AL3MBTL1
SCHEMBL6843532 0.76 GHSR (0.36) HTTMEN1MAPTKMT2AMMP13
SCHEMBL21585955 0.74 LMNA (0.34) LMNAMAPTKMT2AL3MBTL1ALDH1A1
SCHEMBL8031445 0.74 PTPN1 (0.38) KMT2AKDM4EALDH1A1
SCHEMBL21586026 0.74 SLC10A2 (0.31) KMT2A
SCHEMBL23454558 0.72 MAOB (0.51) MAOBMAOASNCANOX1HTT
SCHEMBL8014423 0.72 SLC6A2 (0.43) LMNAGAAMAPTL3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3210977-B1 NOVEL AMINOALKYL BENZOTHIAZEPINE DERIVATIVE AND USE THEREOF CJ HEALTHCARE CORP (KR) 2019-03-20 EP disclosed
US-9890129-B2 Aminoalkylbenzothiazepine derivatives and uses thereof CJ HEALTHCARE CORPORATION (KR) 2018-02-13 US disclosed
US-20170283386-A1 NOVEL AMINOALKYLBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF CJ HEALTHCARE CORPORATION (KR) 2017-10-05 US disclosed
EP-3210977-A2 NOVEL AMINOALKYL BENZOTHIAZEPINE DERIVATIVE AND USE THEREOF CJ Healthcare Corporation (KR) 2017-08-30 EP disclosed
EP-1345918-B1 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS ASTRAZENECA AB (SE) 2007-04-18 EP disclosed
US-7192945-B2 Benzothiazepine derivatives ASTRAZENECA AB (SE) 2007-03-20 US disclosed
US-20040067933-A1 Chemical compounds ELOBIX AB (SE) 2004-04-08 US disclosed
EP-1345918-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2003-09-24 EP disclosed
WO-2002050051-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067933-A1 Chemical compounds SLC10A2, SLC10A1, ABCB11 MAOB 1297/4885MAOA 2293/4885SNCA 4757/4885
US-20170283386-A1 NOVEL AMINOALKYLBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF SLC10A2, TMPRSS15, HTR5A MAOB 582/4885MAOA 999/4885SNCA 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.